Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A. Fisher, K Turner, Tonny Veenith et al.|UCL Discovery (University College London)|2022Cited by 58
Protocol for the Tessa Jowell BRAIN MATRIX Platform StudyColin Watts, Lucinda Billingham, Joshua Savage et al.|BMJ Open|2022Cited by 12
Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trialBenjamin A. Fisher, Pamela Kearns, Tonny Veenith et al.|medRxiv|2021Cited by 7
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adultsTonny Veenith, Simon Gates, Benjamin A. Fisher et al.|BMJ Open|2021Cited by 6
CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adultsTonny Veenith, Simon Gates, Benjamin A. Fisher et al.|medRxiv|2021Cited by 4